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Objectives The aim of this study was to assess the impact of the diagnosis of pulmonary hypertension (PH) on mortality,
morbidity, and health services utilization (HSU) in an adult congenital heart disease (CHD) population.
Background Although PH is a well-recognized complication of CHD, population-based studies of its significance on the sur-
vival and functional capacity of patients are uncommon.
Methods A retrospective longitudinal cohort study was conducted in an adult CHD population with 23 years of follow-up,
from 1983 to 2005. The prevalence of PH was measured in 2005. Mortality, morbidity, and HSU outcomes were
compared between patients with and without diagnoses of PH using multivariate Cox (mortality and morbidity)
and Poisson (HSU) regression models within a subcohort matched for age and CHD lesion type.
Results Of 38,430 adults alive with CHD in 2005, 2,212 (5.8%) had diagnoses of PH (median age 67 years, 59%
women). The diagnosis of PH increased the all-cause mortality rate of adults with CHD more than 2-fold com-
pared with patients without PH (hazard ratio [HR]: 2.69; 95% confidence interval [CI]: 2.41 to 2.99). Morbid com-
plications including heart failure and arrhythmia occurred with a 3-fold higher risk compared with patients with-
out PH (HR: 3.01; 95% CI: 2.80 to 3.22). The utilization of inpatient and outpatient services was increased,
especially cardiac catheterization, excluding the index diagnostic study (rate ratio: 5.04; 95% CI: 4.27 to 5.93)
and coronary and intensive care hospitalizations (rate ratio: 5.03; 95% CI: 4.86 to 5.20).
Conclusions A diagnosis of PH in adults with CHD is associated with a more than 2-fold higher risk for all-cause mortality and
3-fold higher rates of HSU, reflecting high morbidity. (J Am Coll Cardiol 2011;58:538–46) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.033Advances in both medical and surgical care have resulted in
an increasing prevalence of adults with congenital heart
disease (CHD) (1). Even without severe cardiac lesions,
these adults have high rates of health care resource utiliza-
tion (2). Pulmonary hypertension (PH) is a well-recognized
complication limiting the survival and functional capacity of
patients with surgically unrepaired, palliated, and in some
cases “repaired” CHD (3–9). The past few decades have
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accepted March 8, 2011.witnessed earlier detection and intervention for CHD, but
the morbidity and mortality of patients with CHD-related
PH remains unknown. Studies of CHD-related PH have
been published from tertiary hospital registry data, with
emphasis on Eisenmenger syndrome and pediatric study
populations (7,10). We sought to assess the impact of the
diagnosis of PH in an adult CHD population by describing
the prevalence of PH and its incremental effect on mortality,
morbidity, and health services utilization (HSU).
Methods
Data sources. In Quebec, Canada, universal access to
health care is provided, and a unique health care number
assigned at birth is systematically linked to all diagnoses,
hospitalizations, and health services rendered. The database
of Régie de l’Assurance Maladie du Québec (RAMQ)
records physicians’ services claims, and the Med-Echo
database records information related to inpatient care.
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July 26, 2011:538–46 Pulmonary Hypertension in Congenital Heart DiseaseA population-based database comprising 71,467 patients
with CHD followed for 1.5 million patient-years was
constructed by merging the 2 administrative provincial data-
bases (1). Diagnostic codes adhered to the International
Classification of Diseases- Ninth Revision (ICD-9). Pa-
tients were identified if they had at least 1 diagnostic code
for CHD and/or CHD-specific surgical procedure (Online
Appendix) made only by cardiologists, primary care physi-
cians, and cardiovascular surgeons and were assigned CHD
diagnoses using a previously defined hierarchical algorithm
(1). By law, attestation of death is sent to the Quebec
Health Insurance Board, making documentation of death
complete with the exception of rare fraudulent omissions.
The database therefore contained comprehensive longitudi-
nal, diagnostic, and therapeutic records of all patient-linked
health care encounters from January 1983 to December
2005 for all Quebec residents with CHD.
The McGill University Health Centre Ethics Board and
the Quebec government agency responsible for privacy of
access to information approved the study.
Study population. For the purposes of this study, we
derived 2 retrospective cohorts from Quebec’s CHD data-
base (Fig. 1) that included patients age 18 years. The
study population for the prevalence objective included all
adults with CHD alive in 2005, irrespective of a PH
diagnosis in the database over the past 23 years. The
matched cohort included adults with their first PH diagno-
sis coding in the database between 1990 and 2005 and
controls of the same age and CHD lesion type but without
diagnoses of PH up until the time when the diagnosis was
made for the cases. Thus, time zero for each matched PH
and non-PH pair was the time of the first PH diagnosis of
the case. When multiple controls were available for match-
ing, 1 was randomly chosen. One-to-one matching was
sought for the 3,005 patients age 18 years, but matches
could not be identified for 233 patients. The final number of
patients in the matched cohort (Fig. 1) was 5,544 (2,772
matched 1:1). The matched cohort excluded subjects with
PH diagnoses from 1983 to 1990 (the washout period) to
increase the yield of newly diagnosed PH cases.
CHD lesions were grouped as either severe CHD,
shunts, valvular, or other (Table 1, column 1). Severe CHD
lesions reflected patients with a high likelihood of cyanosis
or requiring surgery early in life.
Study design. The PH period prevalence was estimated in
2005 as the proportion of patients in the prevalence cohort
that received initial PH diagnoses between January 1983
and December 2005. The effect of a PH diagnosis on the
mortality, morbidity, and HSU of patients with CHD was
estimated with a retrospective matched cohort, whereby
patients with diagnoses of PH were matched for age, CHD
lesion type and time to non-PH patients. Subjects in the
matched cohort were followed for a maximum of 15 years,
until they experienced an outcome of interest or to the end
of the study, whichever occurred first. Once selected as acontrol, a subject was kept in all
analyses, regardless of whether
he or she subsequently developed
PH.
Measurements. PH MEASURE-
ENT. Patients with PH were
ncluded if a diagnosis of primary
r secondary PH (Online Ap-
endix) was made by selected
pecialists (cardiologists, pul-
onologists, pediatricians, car-
iothoracic surgeons, anesthe-
ists, and emergency and general
hysicians) in the RAMQ or
ed-Echo databases.
OUTCOMES MEASUREMENT
(MATCHED COHORT). Death
uring follow-up in the matched
ohort defined mortality. Morbid
omplications assessed are pre-
ented in the Online Appendix
ith identifying ICD-9 codes.
SU was measured in the first 5 years of follow-up using
atabase-specific codes for physician specialty, medical pro-
edure, and institution type, including outpatient consulta-
ions with cardiologists, pulmonologists, cardiothoracic sur-
eons, neurosurgeons, anesthesiologists, hematologists,
eurologists, obstetricians, pediatricians, radiologists, neph-
ologists, geriatricians, and general, family, and emergency
hysicians; hospitalization days; emergency department vis-
ts and intensive and coronary care unit admissions; and
chocardiography and cardiac catheterization (excluding the
ndex diagnostic catheterization or echocardiographic study
erformed within 1 year of the first PH diagnosis coding).
CONFOUNDERS MEASUREMENT (MATCHED COHORT).
Confounders included age, sex, CHD lesion, clinical diag-
noses known to be risk factors for PH and mortality, and the
overall burden of disease measured by the Charlson index
(11). Age and CHD lesion type groups (Table 1) were
controlled for by matching. Sex, confounding clinical diag-
noses, and the overall burden of disease were controlled for
by statistical adjustment.
Confounding medical diagnoses were identified using
ICD-9 codes (Online Appendix) and measured for each PH
case–non-PH control pair within the 5 years before the time
when the PH case was diagnosed, with the exception of
human immunodeficiency virus infection (10 years before).
Higher index scores have been associated with increased
morbidity and mortality (12).
Statistical analysis. Descriptive statistics include medians,
interquartile ranges, and proportions. The prevalence of PH
was defined as the ratio between the number of adult
patients with CHD alive in 2005 who had PH diagnoses
from 1983 to 2005 and the total adult CHD population
Abbreviations
and Acronyms
ASD  atrial septal defect
CHD  congenital heart
disease
CI  confidence interval
HR  hazard ratio
estimated from Cox
proportional hazards
regression
HSU  health services
utilization
ICD-9  International
Classification of Diseases-
Ninth Revision
PH  pulmonary
hypertension
RR  rate ratio estimated
from Poisson regression
VSD  ventricular septal
defectalive in 2005.
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Pulmonary Hypertension in Congenital Heart Disease July 26, 2011:538–46The effect of PH diagnosis on mortality in different age
groups was analyzed using Kaplan-Meier plots stratified by
age groups (18 to 39 years, 40 to 64 years, and 65 years)
in the matched cohort.
Regression analyses adjusted for confounding variables
estimated the effect of PH diagnosis on morbidity and
mortality (Cox regression) and HSU (Poisson regression)
outcomes. The regression analyses were not adjusted for
matching, because no imbalance was expected between the
exposed and unexposed study subjects with respect to loss to
follow-up and/or missing data in administrative databases
(13). The morbidity outcome was defined as the time to the
first of any of the 9 PH morbid outcome conditions (Online
Appendix). All confounders were chosen on the basis of a
priori knowledge and retained in the model regardless of
their statistical significance. The proportionality of hazards
assumption was assessed using the plot of the log(–log
(estimated survival distribution function)) versus log (time),
with no violation detected. From the Poisson analysis, we
report rate ratios (RRs) and 95% confidence intervals (CIs),
while from the Cox analysis we report hazard ratios (HRs)
and 95% CIs. All statistical analyses were performed using
SAS version 9.1 (SAS Institute Inc., Cary, North Carolina).
Sensitivity analyses. To maximize the identification of PH
Figure 1 Study Population and Design
The figure illustrates the derivation of the study population for the prevalence andcases, the main analyses included all PH diagnoses made byselected specialists, irrespective of whether a diagnostic test
for PH was performed at the time of the first PH coding in
the database (some diagnoses are carried over from visits
occurring before the start of the database). Acknowledging
that cardiac catheterization is the clinical reference standard
to diagnose PH, we performed a sensitivity analysis re-
stricted to PH and non-PH pairs for which the PH case had
a cardiac catheterization within 1 year of the first PH
diagnosis.
Results
PH prevalence. The clinical characteristics of the preva-
lence cohort are presented in Table 1. Of 38,430 adults alive
with CHD in 2005, 2,212 had diagnoses of PH (prevalence
58 in 1,000). Patients with CHD-related PH were older
(difference in median age 26 years), and there were propor-
tionately more women in the CHD population with PH
compared with those without PH. Shunts were the most
common type of CHD lesion among patients with PH.
PH outcomes. When PH complicated adults with CHD,
the risks for all outcomes assessed were increased compared
with patients without PH (Figs. 2 and 3).
All-cause mortality risk was more than 2-fold higher for
ed cohorts. CHD  congenital heart disease; PH  pulmonary hypertension.matchpatients with PH diagnoses compared with those without
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July 26, 2011:538–46 Pulmonary Hypertension in Congenital Heart Disease(adjusted HR: 2.69; 95% CI: 2.41 to 2.99; p  0.001).
aplan-Meier plots of the matched cohort showed the
reatest impact of a diagnosis of PH on the younger age
roup relative to their counterparts without PH (Fig. 4).
urthermore, there was an impact on mortality within the
rst few years after a PH diagnosis in all age groups, as
ndicated by early plot divergence.
The risk for morbidity was 3-fold higher in patients with
HD with PH compared with those without (HR: 3.08;
5% CI: 2.87 to 3.30; p  0.001). Heart failure and
rrhythmia were the most frequent complications, occurring
t least once in 31% and 28% of patients with CHD-related
H during follow-up, respectively (data not shown).
Inpatient and outpatient clinical visits for any reason were
ncreased in patients with PH (Fig. 3). Hospitalization days
ere increased more than 3-fold compared with those
ithout PH (RR: 3.40; 95% CI: 3.36 to 3.44; p  0.0001),
specially to coronary or intensive care facilities (RR: 5.03;
5% CI: 4.86 to 5.20; p  0.0001). Rates of cardiac
atheterization (HR: 5.04; 95% CI: 4.27 to 5.93; p 
Clinical Characteristics of the Prevalence CohorTable 1 Clinical Characteristics of the Prev
Variable
Adults With
(n  38,43
Age (yrs) 42 (28–
Shunts CHD 35 (24–
Severe CHD 33 (25–
Valvular CHD 44 (27–
Other CHD 56 (37–
Women 21,614 (56%
Death 623 (2%)
CHD lesion classification
Shunts 15,724 (41%
ASD 7,122 (19%
VSD 6,651 (17%
Atrioventricular canal defect 1,321 (3%)
Patent ductus arteriosus 630 (2%)
Severe 2,259 (6%)
Tetralogy of Fallot 1,191 (3%)
Truncus arteriosus 193 (1%)
Transposition of the great arteries 438 (1%)
Univentricular heart 326 (1%)
Ebstein’s anomaly 111 (1%
Valvular 5,374 (14%
Congenital aortic stenosis 1,380 (4%)
Congenital mitral regurgitation 1,389 (4%)
Pulmonary valve anomalies 1,270 (3%)
Other valvular 1,332 (3%)
Other 15,073 (39%
Coarctation of the aorta 765 (2%)
Unspecified 14,308 (37%
Values are median (IQR) or n (%). Clinical characteristics in 2005 of ad
the distribution of different cardiac congenital lesions among subject
different cardiac congenital lesions can be estimated by dividing the
adults with that lesion (column 2).
ASD  atrial septal defect; CHD  congenital heart disease; IQR 
defect..0001) and echocardiography (HR: 3.08; 95% CI: 2.96 to t.21; p  0.0001) after the index diagnosis of PH were
ignificantly higher compared with patients without PH.
ensitivity analyses. With the matched cohort study pop-
lation restricted to patients who underwent cardiac cathe-
erization within 1 year of the index PH diagnosis (n 
61), the impact of PH on outcomes was either similar
mortality HR: 2.34; 95% CI; 1.92 to 2.85; morbidity HR:
.09; 95% CI: 2.72 to 3.52; hospitalization RR: 3.89; 95%
I: 3.81 to 3.98; outpatient visits RR: 1.45; 95% CI: 1.43 to
.47; emergency department visits RR: 1.79; 95% CI: 1.72
o 1.88; echocardiography RR: 3.76; 95% CI: 3.52 to 4.03)
r stronger (days in coronary or intensive care units RR:
.41; 95% CI: 6.04 to 6.80) than the main analyses. Thus,
esults from the main analyses were either not affected by
he inclusive noninvasive definition of PH or biased toward
he null.
iscussion
n this large population-based study, we have described for
e Cohort
CHD With PH
(n  2,212)
CHD Without PH
(n  36,218) p Value
67 (51–77) 41 (27–61) 0.001
63 (45–76) 34 (24–49) 0.001
39 (28–55) 33 (24–44) 0.001
67 (55–76) 43 (27–63) 0.001
73 (62–80) 54 (36–71) 0.001
1,313 (59%) 20,301 (56%) 0.002
142 (6%) 481 (1%) 0.001
837 (38%) 14,887 (41%) 0.001
571 (26%) 6,551 (18%) 0.001
153 (7%) 6,498 (18%) 0.001
86 (4%) 1,235 (3%) 0.230
27 (1%) 603 (2%) 0.110
149 (7%) 2,110 (6%) 0.093
70 (3%) 1,121 (3%) 0.850
15 (1%) 178 (1%) 0.230
26 (1%) 412 (1%) 0.870
30 (1%) 296 (1%) 0.007
8 (1%) 103 (1%) 0.510
373 (17%) 5,001 (14%) 0.001
82 (4%) 1,298 (4%) 0.001
176 (8%) 1,213 (3%) 0.001
24 (1%) 1,246 (3%) 0.001
91 (4%) 1,244 (3%) 0.001
853 (39%) 14,220 (39%) 0.8369
20 (1%) 745 (2%) 0.001
833 (40%) 13,475 (37%) 0.670
he prevalence cohort with and without PH and CHD. The table depicts
nd without PH. Prevalence of PH in year 2005 among subjects with
of patients with PH and a given lesion (column 3) by the number of
artile range; PH  pulmonary hypertension; VSD  ventricular septaltalenc
CHD
0)
63)
51)
44)
65)
72)
)
)
)
)
)
)
)
)
ults in t
s with a
numberhe first time the significant adverse effect of a PH diagnosis
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range of CHD defects. PH afflicted 6% of adults alive with
CHD. Although the median age of these adults was in the
sixth decade of life, PH was associated with a more than
doubling of all-cause mortality and tripling of morbid
complications that were reflected by a more than 3-fold
increase in hospitalization days, especially to coronary and
intensive care units.
Prevalence. The prevalence of CHD-related PH has been
reported with a wide range (6–9), dependent on the entry
diagnostic criteria and populations studied.
Estimates of the prevalence of PH among the general
adult CHD population have been extrapolated from tertiary
hospital registries of patients with the entire spectrum of
pulmonary arterial hypertension. The prevalence of patients
with CHD-related PH ranges between 1.7 and 12.8 cases
Figure 2 HRs for Mortality and Morbidity in Adults With CHD W
The pooled effects of PH and sex are from the same model, while sex effects in t
for all-cause mortality and morbid complications (represented by a hazard ratio [HRper million adults from these registries in Western countries(14,15). In contrast to these studies, our source population
was adults with CHD.
The risk for developing CHD-related PH is influenced
by multiple factors, including increased pulmonary blood
flow, pressure, the timing and success of surgical correction,
extracardiac abnormalities, and genetic factors. Eisen-
menger syndrome is the most advanced expression of
CHD-related PH, and advances in treatments have halved
the prevalence of Eisenmenger syndrome in the Western
world over the past 50 years (16). The prevalence of
CHD-related PH has been reported mostly in patients with
septal defects and ranged from 6% to 28% (6,10,17).
However, in all these studies, patients attending specialized
tertiary referral hospitals and those with Eisenmenger syn-
drome were overrepresented.
Because provincial databases capture medical visits be-
nd Without PH
and no-PH groups are from stratified models. The figure depicts increased risk
with similar risk to men and women with PH. Abbreviations as in Figure 1.ith a
he PH
] 1)yond the tertiary hospital setting, our reported prevalence is
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Unrestrictive ventricular septal defects (VSDs) expose the
pulmonary circulation to higher pressures and are more
likely to induce early and more severe pulmonary vascular
disease than atrial septal defects (ASDs). However, the
prevalence of ASDs in adults with CHD-related PH was
higher than that of VSDs in our study. The older age of
patients with ASDs and PH compared with those with
VSDs and PH (median age 67.4  16.9 years vs. 53.5 
21.4 years) is a likely explanation. Additionally, a large
number of adults with restrictive VSDs, which are known to
be the second most common congenital heart defect after
bicuspid aortic valves (18) are included in the population-
based database.
Mortality associated with PH and CHD. Published sur-
vival data of patients with CHD-related PH have been
mostly limited to primary PH, selected CHD diagnoses,
and Eisenmenger syndrome. Recently, mortality among
adults with CHD in the Dutch Congenital Corvitia registry
was compared with that among the general population (19).
Pulmonary arterial hypertension predicted a 3-fold increase
in all-cause mortality after adjustment for age, sex, and
Figure 3 RRs for HSU in Adults With CHD With and Without PH
PH confers an increased rate of all health services utilization (HSU) outcomes. Th
exclude those performed within 1 year of receiving the first PH diagnosis. AbbreviaCHD severity. Our study reinforces the high mortalityrisk associated with PH even when compared with a
control population of patients with CHD without PH.
The Euro Heart Survey followed 531 adults with pulmo-
nary arterial hypertension and either ASDs or VSDs for
5 years and reported a median mortality in patients with
Eisenmenger syndrome of 20.6% (10). Estimated survival
for patients with PH but not Eisenmenger syndrome
ranged from 93.1% with a closed VSD to 97.2% with an
open ASD. In another study of patients with Eisen-
menger syndrome (mean age at last follow-up 33 years),
followed for a mean duration of 31 years, 35% of patients
had died (4). Differences in study populations and the
lack of a specific ICD-9 code to identify patients with
Eisenmenger syndrome preclude direct comparisons with
our study. Nonetheless, given that our population-based
study likely included a greater proportion of milder
CHD, the mortality risk is at least doubled with PH. We
appropriately report all-cause mortality, because patients
with severe PH may die of sudden cardiac death, heart
failure, hemoptysis, brain abscess, thromboembolism,
complications of pregnancy or noncardiac surgery
(9,20,21). In a sensitivity analysis that included only
ratios (RRs) for echocardiography and cardiac catheterization
as in Figure 1.e rate
tionspatients eligible for biventricular repair, the effect of a
p
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Pulmonary Hypertension in Congenital Heart Disease July 26, 2011:538–46diagnosis of PH on mortality remained unchanged (HR:
2.69; 95% CI: 2.41 to 2.99, data not shown).
Morbidity. Morbid events have not been previously re-
orted in patients with CHD-related PH less severe than
isenmenger syndrome.
In the Second Natural History Study of CHD, at least 1
f the following morbid complications occurred at a rate of
23 per 10,000 patient-years of follow-up in patients with
edically and surgically managed VSDs: endocarditis, heart
ailure, brain abscess, syncope, angina, myocardial infarc-
Figure 4
Kaplan-Meier Plots of Cumulative Survival in Adults
With CHD According to PH Status Stratified by 2
Age Groups
For each PH case–non-PH control pair, the time zero corresponds to the date
of the first PH diagnosis of the PH case. Abbreviations as in Figure 1.ion, stroke, and pacemaker implantation (6). Morbidityrelated to PH was not examined in this study. Not unex-
pectedly, the rate of echocardiography and cardiac catheter-
ization was significantly higher in patients with CHD-
related PH than in those without PH.
Although morbidity was reported in the Euro Heart Survey,
it was described in patients with cyanotic defects, with more
than half having Eisenmenger syndrome (22). The reported
1.86 outpatient visits per patient-year and 71 echocardio-
graphic evaluations per 100 patient-years for patients with
cyanotic defects underscores the substantial demand on health
care resources compared with noncyanotic defects.
Sex differences. In the National Institutes of Health Regis-
try, women are affected by idiopathic pulmonary arterial
hypertension, independent of age, more frequently (female/
male ratio 1.7:1) (23). A Dutch nationwide registry study of
adults with selective CHD reported a 25% higher risk in
women (24), a result confirmed in our study. The results of our
Poisson modeling an interaction term between sex and PH
suggest that the differences in the sex distribution of CHD
lesions most likely explains the increased prevalence of PH in
women with CHD rather than biological or genetic suscepti-
bility. This is consistent with a female predominance in CHD
lesions, such as septal defects and patent ductus arteriosus,
which provide an anatomical substrate for developing PH. Sex
findings were remarkable for the minimal impact of sex on
morbidity and mortality: when we tested the interaction
between PH and sex, the impact of PH on mortality and
morbidity was similar (Fig. 2) in both sexes. Our findings are
consistent with those of Verheugt et al. (24), in which women
had a higher risk for PH than men, but the same risk for death.
Limitations and strengths of the study design. We em-
phasize several limitations of our study. Foremost are
misclassification errors related to PH status inherent to
using ICD-9 codes as billing codes. Clinical studies have
defined PH by echocardiography or cardiac catheterization
(25). In our study, the quantitative results of echocardiog-
raphy or cardiac catheterization were unavailable, so we
describe the impact related to a diagnosis of PH by
administrative coding rather than PH itself. We recognize
that administrative coding reflects neither the biological
onset of PH nor the severity of pulmonary vascular hemo-
dynamic changes, and pulmonary arterial hypertension
could not be distinguished from pulmonary venous hyper-
tension. Additional clinical information for post hoc anal-
ysis was limited by the local ethics board and the Quebec
government agency that approved the study, who did not
allow individual patients to be identified by name or hospital
number. However, the fact that our findings were applicable
to all forms of PH underscores the negative prognostic
implications of a PH diagnosis. Further studies are needed
to differentiate the relative impact of pulmonary arterial
hypertension with expected resistance changes in the pul-
monary vascular bed in contrast to pulmonary venous
hypertension. To address possible errors in the measure-
ment of PH in the administrative databases, we undertook
a sensitivity analysis restricted to patients with PH who
545JACC Vol. 58, No. 5, 2011 Lowe et al.
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PH diagnosis coding. The validity of a diagnosis of PH was
supported by the high proportion of patients who under-
went echocardiography or cardiac catheterization within 1
year of the first PH coding (31% of patients underwent
both, and 89% underwent at least 1, of the 2 diagnostic
procedures). The results of the sensitivity analysis support
the validity of the main analyses, without overestimation of
the outcomes with a more inclusive definition of PH. We
minimized false-positive cases of PH by including coding
only by selected physicians familiar with PH patients.
Stricter criteria were unnecessary, because results remained
unchanged in further sensitivity analyses that excluded 108
PH and non-PH pairs whose diagnoses were not made
during hospitalization by cardiologists or pulmonologists
(mortality HR: 2.70; 95% CI: 2.42 to 3.01). Although
undercoding of PH is possible, our reported prevalence of
6% is consistent with results from another population-based
study of CHD-related PH (17). False-negative cases were
unlikely in the prevalence cohort, because subjects had 23
years to be identified with PH. In the matched cohort, the
number of false-negative cases (subjects with PH analyzed
as controls) may have been higher, but this selection bias is
likely to result in more conservative estimates (assuming
that the effect of PH on outcomes is never protective).
We minimized the misclassification of CHD diagnoses
by using all available data for a given subject over the 23
years of database follow-up and manual audits for the CHD
diagnoses on random samples of 28% of subjects (1).
Our list of potential confounders is comprehensive, but
we cannot exclude residual confounding factors that are
unknown or could not be measured within administrative
databases. For example, the effects of cardiac surgery on PH
could not be assessed, because of the limited time window of
our administrative databases. However, assuming that sur-
gery for CHD prevents the onset and adverse sequelae of
PH, this unmeasured confounding factor is likely to bias the
estimates toward the null.
We may have excluded subjects who failed to come into
contact with the Quebec health care system during the study
period. However, this is unlikely given that the study period
spanned more than 23 years. Furthermore, in our previous
work assessing the prevalence of CHD, on the basis of an
estimated annual net migration into the province of 24,000
people, we may have overestimated the number of patients
with CHD by only 0.05% (1).
Our results can be generalized to wider Canada, because
Quebec accounts for one-quarter of Canada’s adult popu-
lation. Although this is not a U.S.-based population study,
standards of care for patients with CHD have largely
followed North American standards (26).
Conclusions
CHD-related PH is not rare and is associated with more
than doubling of all-cause mortality and more than triplingof morbid complications and hospitalization days compared
with patients without PH. With an increasing population of
adults surviving with CHD, the burden of disease associated
with PH is expected to increase. Patients with CHD have
been under-represented in trials of PH, and the findings of
this study calls for more investigations of PH-targeted
therapy in CHD. Our findings should be of interest to
future health care resource planners.
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APPENDIX
For ICD-9 codes for CHD, PH, and morbid outcomes,
please see the online version of this article.
